We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunohistochemical Test Validated for Diagnosis of Hepatocellular Carcinoma

By LabMedica International staff writers
Posted on 07 Apr 2009
Print article
Image: Light micrograph of a metastatic carcinoma in the human liver, showing normal liver cells in contrast with malignant tumor cells (Photo courtesy of John Burbidge / SPL).
Image: Light micrograph of a metastatic carcinoma in the human liver, showing normal liver cells in contrast with malignant tumor cells (Photo courtesy of John Burbidge / SPL).
A monoclonal antibody product (clone 1G12) for detection of Glypican-3 (GPC3) has been validated for use as an immunohistochemical test for diagnosis of Hepatocellular Carcinoma (HCC).

The antibody validation studies were performed at PhenoPath Laboratories (Seattle, WA, USA) with formalin fixed paraffin embedded (FFPE) tissue sections used in routine immunohistochemistry tests. A series of tissues (normal and tumor) that would be part of the differential diagnosis in a clinical setting were tested to determine what percent might be positive. With the 1G12 antibody to GPC 3, 88% (38/43) of cases with hepatocellular carcinoma showed strong positive immunostaining. In all observed cases, nonneoplastic liver that was present in the specimen was negative or showed rare cells positive for Glypican-3. All 21 cases of nodules in cirrhotic liver were negative for Glypican-3.

The monoclonal antibody (clone 1G12) was produced by of BioMosaics (Burlington, VT, USA), a biotechnology company engaged in the development and commercialization of products for the early diagnosis, prediction, and monitoring of cancer. The antibody is available in concentrated form or as a ready-to-use, pre-diluted product for IHC. Both formats are suitable for use with manual protocols or in automated immunostaining instruments.

Hepatocellular Carcinoma, is one of the most common and aggressive malignant tumors worldwide, causing an estimated one million deaths annually. The main causative agents are hepatitis B virus (HBV), hepatitis C virus (HCV), as well as alcoholic cirrhosis and non-alcoholic steatohepatitis (NASH), which is associated with obesity and diabetes. The incidence of HCC has been steadily increasing over the past ten years and is expected to continue to rise over the next decade.

PhenoPath Laboratories is a reference pathology laboratory providing diagnostic immunohistochemistry (IHC), in situ hybridization (ISH), flow cytometry, and other molecular pathology services to pathologists throughout the United States.

Related Links:

PhenoPath Laboratories
BioMosaics


Gold Member
Troponin T QC
Troponin T Quality Control
Automated Blood Typing System
IH-500 NEXT
New
Urine Strips
11 Parameter Urine Strips
New
Vitamin B12 Test
CHORUS CLIA VIT B12

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.